ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Acute lymfatische- en 'mixed phenotype' leukemie (ALL/MPAL) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Acute lymfatische leukemie' van de HOVON Leukemie werkgroep.

Literatuur

  1. Arber D.A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical and genomic data. Blood 2022 - 140 (11): 1200-1228
  2. Weinberg O.K. et al. The international consensus classification of acute leukemias of ambiguous lineage. Blood 2023 - 141 (18): 2275-2277
  3. Gokbuget N et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leukemia & Lymphoma 2020 doi: 10.1080/10428194.2020.1780583)
  4. Gokbuget N et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018; 131(14): 1522-1531. doi: 10.1182/blood-2017-08-798322
  5. Giebel S et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone marrow transplantation 2018. e-pub ahead of print 2018/11/06; doi: 10.1038/s41409-018-0373-4
  6. Gokbuget N et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology 2019; 24(1): 337-348. e-pub ahead of print 2019/02/14; doi: 10.1080/16078454.2019.1567654
  7. Giebel S. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European working group for adult acute lymphoblastic leukemia (EWALL) and the acute leukemia working party of the European society for blood and marrow transplantation (EBMT). Bone marrow transplantation 2018. doi: 10.1038/s41409-018-0373-4
  8. Hrabovsky S et al. Comparison of real-time quantitative polymerase chain reaction and eight-color flow cytometry in assessment of minimal residual disease in adult acute lymphoblastic leukemia. Clinical lymphoma, myeloma & leukemia 2018; 18(11): 743-748. e-pub ahead of print 2018/07/31; doi: 10.1016/j.clml.2018.06.030
  9. Arber D.A. et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 127:2391-2405
  10. Wolach O. and Stone R.M. How I treat mixed-phenotype acute leukemia. Blood. 2015 125:2477-2485
  11. Dhedin N. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 2015 Apr 16; 125(16):2486-96; quiz 2586
  12. Ribera J-M. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescent and adults according to early cytologic response and minimal residual disease after consolidation assesed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014 May 20; 32(15):1595-604
  13. Zuckerman T. et al. How I treat hematologic emergencies in adults with acute leukemia. Blood 2012 Sep 6;120(10):1993-2002
  14. Bassan R. et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual diesease (MRD) in adult acute lymphoblastic leukemia (ALL). Blooed 2009. Apr 30;113(18):4153-62
  15. Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 106: 2912-2919
  16. Schuurhuis GJ et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12): 1275-1291. doi: 10.1182/blood-2017-09-801498
  17. Heuser M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138(26): 2753-2767. doi: 10.1182/blood.2021013626

 

Ga terug naar de ALL/MPAL homepage of lees meer over ALL/MPAL:

Ga terug naar de algemene homepage Behandelprotocollen.